Oncology (all articles)
NCCN Guideline: Pediatric Acute Lymphoblastic Leukemia
16 Jan, 2020 | 02:42h | UTC
Position Statement on the Role of Percutaneous Ablation in Renal Cell Carcinoma
16 Jan, 2020 | 02:36h | UTC
[Abstract Only] Cohort Study: Colorectal Cancer in Ulcerative Colitis
16 Jan, 2020 | 02:34h | UTCColorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study – The Lancet (link to abstract – $ for full-text)
Commentary: Association Between Colorectal Cancer and Ulcerative Colitis – The ASCO Post (free)
FDA Safety Communication: Possible Increased Risk of Cancer with Weight-loss Medicine Lorcaserin
15 Jan, 2020 | 08:02h | UTCCommentaries: CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA – TCTMD (free) AND FDA Warning: Weight Loss Drug Belviq May Increase Cancer Risk- Forbes (free)
Review: Surveillance in Patients with Diffuse Large B Cell Lymphoma
15 Jan, 2020 | 01:07h | UTCSurveillance in Patients with Diffuse Large B Cell Lymphoma – Mayo Clinic Proceedings (free)
Meta-Analysis: Multiple Drug Combinations of Bortezomib, Lenalidomide, and Thalidomide for First‐line Treatment in Adults with Transplant‐Ineligible Multiple Myeloma
15 Jan, 2020 | 00:54h | UTCMultiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis – Cochrane Library (free)
Commentary: Featured Review: Reducing uncertainties in choosing first-line treatment in newly diagnosed multiple myeloma – Cochrane Library (free)
ASCO Guideline Update: Estrogen and Progesterone Receptor Testing in Breast Cancer
14 Jan, 2020 | 00:27h | UTCNews Release: Updated Breast Cancer Guideline Refines Testing to Better Identify Patients Likely to Benefit from Treatment – College of American Pathologists (free)
ESMO Guideline: Marginal Zone Lymphomas
14 Jan, 2020 | 00:26h | UTC
Review: New Oral Anti-Cancer Drugs and Medication Safety
14 Jan, 2020 | 00:11h | UTCNew Oral Anti-Cancer Drugs and Medication Safety – Deutsches Ärzteblatt international (free)
Study: One Cycle of Bleomycin/Etoposide/Cisplatin May Be as Effective as Two for Patients With Testicular Cancer
14 Jan, 2020 | 00:04h | UTC
Special Issue: Practical Aspects of Palliative Care
12 Jan, 2020 | 21:25h | UTCHomepage: Palliative Care – Medicine (free articles)
– Palliative care: introduction
– Pain control in palliative care
– Interventional management of pain in cancer and palliative care
– Nausea and vomiting in palliative care
– Constipation and malignant bowel obstruction in palliative care
– Breathlessness in advanced disease
– Psychiatric conditions in palliative medicine
– Emergencies in palliative care
– Palliative care in non-malignant disease
– Management of less common symptoms in palliative care
– Complications of systemic anti-cancer treatment
– Care in the last hours and days of life
– Advance care-planning and clinical decision-making
– Ethical principles in end-of-life care
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer
12 Jan, 2020 | 21:04h | UTC
Recommendation for Supportive Care in Patients Receiving Concurrent Chemotherapy and Radiotherapy for Lung Cancer
12 Jan, 2020 | 21:02h | UTC
Systematic Review: Prehabilitation Before Major Intra-abdominal Cancer Surgery
12 Jan, 2020 | 20:45h | UTC
Study: Surgical Results of Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
12 Jan, 2020 | 20:47h | UTCBreast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary: Despite effective therapy, US rate of breast conservation lower than other countries – Brigham and Women’s Hospital (free)
Related Commentary on Twitter
https://twitter.com/JAMASurgery/status/1214954932144672768
Global Burden of Cancer Attributable to Infections in 2018: A Worldwide Incidence Analysis
9 Jan, 2020 | 23:44h | UTC
Related Commentary on Twitter
New @IARCWHO data show that 2·2 million new cancer cases were attributable to infections in 2018, representing 13% of all cancer cases (excluding non-melanoma skin cancers). H pylori was responsible for most new cases, followed by #HPV, #HBV, and #HCV. https://t.co/X4oNNV7YXf pic.twitter.com/ZCue5yFMn3
— The Lancet Global Health (@LancetGH) December 19, 2019
Study: Increased Physical Activity Linked Lower Cancer Risk
9 Jan, 2020 | 23:35h | UTCCommentaries: Report links recommended physical activity levels to lower risk of seven cancers – American Cancer Society (free) AND Getting the recommended amount of physical activity is tied to lower risk of cancer, study says – CNN (free)
[Abstract Only] Study: Sustained Weight Loss Linked to Lower Risk of Breast Cancer
8 Jan, 2020 | 22:20h | UTCSustained weight loss and risk of breast cancer in women ≥50 years: a pooled analysis of prospective data – JNCI: Journal of the National Cancer Institute (link to abstract – $ for full-text)
Commentaries: Large study links sustained weight loss to reduced breast cancer risk – American Cancer Society (free) AND Weight loss linked to lower chance of getting breast cancer for women over 50 – NHS Choices (free) AND Study Links Sustained Weight Loss to Reduced Breast Cancer Risk – The ASCO Post (free)
[Abstract Only] Randomized Trial: Olanzapine Plus Standard Antiemetic Therapy for the Prevention of Chemotherapy-induced Nausea and Vomiting
8 Jan, 2020 | 22:12h | UTCOlanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Related Commentary on Twitter
in phase III trial, patients received anti-emetic combination plus placebo or 5 mg olanzapine (dose lower than standard to avoid somnolence); 5 mg dose was deemed effective https://t.co/urEz3AKFdA
— NatureRevClinOncol (@NatRevClinOncol) December 19, 2019
[Abstract Only] Randomized Trial: Four Cycles of R-CHOP Non-inferior to Six Cycles of R-CHOP in Patients with Aggressive B-cell non-Hodgkin Lymphoma and Favorable Prognosis
8 Jan, 2020 | 21:49h | UTCFour versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Related Commentary on Twitter
Four cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): The new standard of care for limited DLBCL with favorable prognosis https://t.co/oAH9dJJGZA
— Georgios Pongas, MD (@pongasg) December 24, 2019
Randomized Trial: Long-term Aromatase Inhibitor Prevents Breast Cancer in High-risk Postmenopausal Women
8 Jan, 2020 | 21:48h | UTCCommentaries: IBIS-II study finds anastrozole reduces breast cancer rates for high risk postmenopausal women – Queen Mary, University of London (free) AND Drug that prevents half of breast cancers carries on working – BBC (free) AND Long-Term Results of IBIS-II: Anastrozole for Breast Cancer Prevention – The ASCO Post (free)
[Abstract Only] Randomized Trial: Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
8 Jan, 2020 | 21:47h | UTCOverall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Overall Survival With the Addition of Daratumumab to VMP in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma -The ASCO Post (free)
Thyroid Nodules: Diagnostic Evaluation Based on Thyroid Cancer Risk Assessment
8 Jan, 2020 | 08:39h | UTCThyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment – The BMJ (free for a limited period)
[Abstract Only] Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
8 Jan, 2020 | 00:51h | UTCCommentaries: SABCS 2019: Adding Tucatinib to Capecitabine/Trastuzumab Improved Survival for Patients With Advanced HER2-Positive Breast Cancer – The ASCO Post (free) AND HER2CLIMB and DESTINY-Breast01 Findings in Heavily Pretreated HER2-positive MBC – ESMO (free)
[Abstract Only] Randomized Trial: Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
8 Jan, 2020 | 00:51h | UTCOverall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Targeted therapy drug helps women with aggressive breast cancer live longer – University of California (free) AND Overall Survival With the Addition of Ribociclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: MONALEESA-3 – The ASCO Post (free)